CytoMed Short Term Investments vs Non Currrent Assets Other Analysis

GDTC Stock   2.29  0.67  22.64%   
CytoMed Therapeutics financial indicator trend analysis is way more than just evaluating CytoMed Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytoMed Therapeutics is a good investment. Please check the relationship between CytoMed Therapeutics Short Term Investments and its Non Currrent Assets Other accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Short Term Investments vs Non Currrent Assets Other

Short Term Investments vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytoMed Therapeutics Short Term Investments account and Non Currrent Assets Other. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between CytoMed Therapeutics' Short Term Investments and Non Currrent Assets Other is -0.52. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of CytoMed Therapeutics Limited, assuming nothing else is changed. The correlation between historical values of CytoMed Therapeutics' Short Term Investments and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of CytoMed Therapeutics Limited are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Short Term Investments i.e., CytoMed Therapeutics' Short Term Investments and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

-0.52
Relationship DirectionNegative 
Relationship StrengthVery Weak

Short Term Investments

Short Term Investments is an item under the current assets section of CytoMed Therapeutics balance sheet. It contains any investments CytoMed Therapeutics Limited undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that CytoMed Therapeutics can easily liquidate in the marketplace.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.
Most indicators from CytoMed Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytoMed Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
The current year's Issuance Of Capital Stock is expected to grow to about 13.7 M, whereas Tax Provision is forecasted to decline to 630.58.
 2022 2023 2024 2025 (projected)
Other Operating Expenses1.4M3.2M3.7M3.9M
Depreciation And Amortization291.8K77.5K69.7K66.2K

CytoMed Therapeutics fundamental ratios Correlations

-0.230.780.040.98-0.67-0.85-0.96-0.910.661.00.230.991.00.99-0.380.88-0.49-0.73-0.660.740.181.0-0.14-0.811.0
-0.23-0.280.96-0.42-0.19-0.280.43-0.120.13-0.22-0.82-0.18-0.23-0.21-0.690.01-0.73-0.490.860.450.88-0.191.0-0.28-0.19
0.78-0.28-0.040.77-0.71-0.65-0.82-0.770.360.790.350.810.790.820.020.89-0.22-0.51-0.640.61-0.070.78-0.21-0.720.8
0.040.96-0.04-0.16-0.4-0.520.17-0.390.290.05-0.780.090.040.06-0.790.26-0.87-0.710.690.670.950.080.98-0.520.08
0.98-0.420.77-0.16-0.57-0.73-0.98-0.820.610.980.390.950.980.97-0.210.81-0.3-0.58-0.790.59-0.020.97-0.34-0.70.97
-0.67-0.19-0.71-0.4-0.570.80.580.77-0.18-0.680.27-0.75-0.68-0.740.5-0.690.570.730.28-0.72-0.48-0.69-0.250.7-0.71
-0.85-0.28-0.65-0.52-0.730.80.730.93-0.72-0.860.27-0.89-0.85-0.850.7-0.860.830.950.24-0.96-0.59-0.87-0.360.89-0.85
-0.960.43-0.820.17-0.980.580.730.83-0.6-0.96-0.36-0.96-0.97-0.960.14-0.840.280.560.8-0.60.06-0.960.350.71-0.95
-0.91-0.12-0.77-0.39-0.820.770.930.83-0.66-0.910.05-0.93-0.91-0.920.52-0.930.720.90.36-0.91-0.45-0.92-0.210.97-0.93
0.660.130.360.290.61-0.18-0.72-0.6-0.660.67-0.040.640.660.59-0.460.69-0.64-0.69-0.20.740.30.670.2-0.670.63
1.0-0.220.790.050.98-0.68-0.86-0.96-0.910.670.210.991.00.99-0.380.88-0.49-0.74-0.660.740.181.0-0.14-0.811.0
0.23-0.820.35-0.780.390.270.27-0.360.05-0.040.210.130.220.210.640.140.610.38-0.64-0.33-0.750.19-0.820.080.21
0.99-0.180.810.090.95-0.75-0.89-0.96-0.930.640.990.130.990.99-0.390.89-0.52-0.76-0.640.770.210.99-0.09-0.820.98
1.0-0.230.790.040.98-0.68-0.85-0.97-0.910.661.00.220.990.99-0.380.88-0.49-0.73-0.660.740.181.0-0.14-0.811.0
0.99-0.210.820.060.97-0.74-0.85-0.96-0.920.590.990.210.990.99-0.370.89-0.48-0.74-0.650.740.20.99-0.13-0.821.0
-0.38-0.690.02-0.79-0.210.50.70.140.52-0.46-0.380.64-0.39-0.38-0.37-0.320.910.81-0.34-0.7-0.93-0.41-0.730.54-0.4
0.880.010.890.260.81-0.69-0.86-0.84-0.930.690.880.140.890.880.89-0.32-0.58-0.8-0.430.870.250.890.09-0.930.89
-0.49-0.73-0.22-0.87-0.30.570.830.280.72-0.64-0.490.61-0.52-0.49-0.480.91-0.580.94-0.31-0.9-0.91-0.52-0.780.77-0.51
-0.73-0.49-0.51-0.71-0.580.730.950.560.9-0.69-0.740.38-0.76-0.73-0.740.81-0.80.94-0.01-0.98-0.77-0.76-0.570.92-0.76
-0.660.86-0.640.69-0.790.280.240.80.36-0.2-0.66-0.64-0.64-0.66-0.65-0.34-0.43-0.31-0.01-0.040.58-0.630.810.17-0.62
0.740.450.610.670.59-0.72-0.96-0.6-0.910.740.74-0.330.770.740.74-0.70.87-0.9-0.98-0.040.670.760.53-0.940.76
0.180.88-0.070.95-0.02-0.48-0.590.06-0.450.30.18-0.750.210.180.2-0.930.25-0.91-0.770.580.670.210.91-0.530.22
1.0-0.190.780.080.97-0.69-0.87-0.96-0.920.671.00.190.991.00.99-0.410.89-0.52-0.76-0.630.760.21-0.11-0.831.0
-0.141.0-0.210.98-0.34-0.25-0.360.35-0.210.2-0.14-0.82-0.09-0.14-0.13-0.730.09-0.78-0.570.810.530.91-0.11-0.36-0.1
-0.81-0.28-0.72-0.52-0.70.70.890.710.97-0.67-0.810.08-0.82-0.81-0.820.54-0.930.770.920.17-0.94-0.53-0.83-0.36-0.84
1.0-0.190.80.080.97-0.71-0.85-0.95-0.930.631.00.210.981.01.0-0.40.89-0.51-0.76-0.620.760.221.0-0.1-0.84
Click cells to compare fundamentals

CytoMed Therapeutics Account Relationship Matchups

CytoMed Therapeutics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets2.9M4.5M3.9M12.4M14.2M14.9M
Short Long Term Debt Total2.3M2.4M3.1M448.0K515.2K489.5K
Other Current Liab326.7K176.1K400.3K643.7K740.2K411.8K
Total Current Liabilities2.1M2.2M3.1M716.9K824.5K783.3K
Total Stockholder Equity359.6K1.9M436.0K8.5M9.8M10.3M
Property Plant And Equipment Net1.7M1.8M1.8M1.6M1.4M1.5M
Net Debt1.6M551.6K2.0M(8.5M)(7.7M)(7.3M)
Retained Earnings(2.3M)(3.7M)(6.1M)(9.3M)(8.4M)(8.0M)
Accounts Payable14.3K34.2K10.9K24.6K28.3K21.2K
Cash668.8K1.9M1.2M9.0M10.3M10.9M
Non Current Assets Total1.8M2.1M2.0M2.3M2.6M2.3M
Non Currrent Assets Other(1.8M)(2.1M)(2.0M)546.7K628.7K660.1K
Cash And Short Term Investments668.8K1.9M1.2M9.0M10.3M10.9M
Net Receivables9.1K3.9K42.8K204.7K235.5K247.2K
Common Stock Shares Outstanding5.9M6.9M7.9M10.6M12.2M8.1M
Short Term Investments32.9K11.3K11.6K47.8K43.0K30.0K
Liabilities And Stockholders Equity2.9M4.5M3.9M12.4M14.2M14.9M
Non Current Liabilities Total464.0K410.0K353.3K407.8K367.0K361.6K
Inventory181.6K319.1K428.0K(204.7K)(184.3K)(175.1K)
Other Current Assets571.7K763.7K856.6K896.8K1.0M688.6K
Other Stockholder Equity(6.3K)1.1M(94.7K)(32.6K)(29.3K)(27.9K)
Total Liab2.5M2.6M3.4M1.1M1.3M2.3M
Total Current Assets1.1M2.4M1.9M10.1M11.6M12.2M
Accumulated Other Comprehensive Income(6.3K)(22.9K)(94.7K)(108.7K)(97.8K)(93.0K)
Short Term Debt1.8M2.0M2.8M40.3K46.3K44.0K
Intangible Assets33.9K23.4K13.7K12.1K10.9K19.0K
Common Stock2.6M4.8M6.6M18.0M20.7M21.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.22)
Revenue Per Share
0.039
Quarterly Revenue Growth
(0.21)
Return On Assets
(0.17)
Return On Equity
(0.26)
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.